Blood Test Might Predict Worsening of MS
By Ernie Mundell HealthDay Reporter
KEY TAKEAWAYS:
-
The progression of multiple sclerosis is particularly difficult to predict, varying widely between patients
-
A new blood test uses a biomarker of nerve cell damage to accurately predict progression over the next two years
-
If the test proves valid, it might help patients and their doctor plan optimal treatments, the researchers said
MONDAY, Nov. 13, 2023 -- One issue hampering the care of people with multiple sclerosis is assessing just how quickly the neurological illness might progress.
Now, a team at the University of California, San Francisco (UCSF), say they've spotted at test that could help do just that.
Blood tests showing elevated levels of Nfl, a "biomarker" indicating nerve damage, seemed to predict with high accuracy a worsening of MS symptoms over the next two years, the researchers found.
That could help patients and their physicians with treatment planning, said a team led by Dr. Ahmed Abdelhak, of the UCSF Department of Neurology and the Weill Institute for Neurosciences.
“This rising of NfL up to two years before signs of disability worsening represents the window when interventions may prevent worsening,” Abdelhak explained in a UCSF news release.
An MS patient's level of disability is typically measured by what's known as the Expanded Disability Status Scale. In the study, Abdelhak's group used the scale to track how quickly symptoms progressed among individuals in a cohort of almost 1,900 patients with MS. Patients were tracked for about 10 years.
The findings highlighted the unpredictability of MS progression. Among the cohort, 570 patients showed a steady worsening of symptoms, while the disease remained relatively stable over the 10-year period.
Blood tests targeting Nfl seemed to predict whose disease would or wouldn't progress.
"Elevated NfL levels were associated with up to a 91% higher risk of worsening disability, with relapse approximately a year later, and up to a 49% higher risk of worsening disability without relapse nearly two years later," the researchers said.
The study was published Nov. 6 in the journal JAMA Neurology.
The study "aligns with recognition that death of nerve cells is a slow process that builds toward permanent disability and means that interventions to protect nerve cells might have time to also stop disability," said study co-senior author Dr. Ari Green, medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center.
Sources
- UCSF news release, Nov. 6, 2023
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
In Experiments, Mice Got ill From Raw Milk Carrying Bird Flu Virus
FRIDAY, May 24, 2024 -- Confirming the dangers of drinking raw cow's milk when the H5N1 avian flu virus is circulating in U.S. dairy herds, researchers found that mice fed the...
FDA Panel Gives Nod to Blood Test for Colon Cancer
FRIDAY, May 24, 2024 -- A U.S. Food and Drug Administration advisory panel on Thursday recommended the approval of a new blood test that can spot colon cancer. The panel voted...
New Steps Towards a Male Birth Control Pill
FRIDAY, May 24, 2024 -- For decades, the responsibility for birth control has fallen largely on women, but new research suggests a birth control pill for men might one day become...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.